Table 3.
Predictors of mortality.
| Sr. number | Author, year of publication | Predictor variable | AHR | 95% CI (upper limit, lower limit) |
|---|---|---|---|---|
| (1) | Hambisa MT et al., 2013 | Age ≥ 40 | 3.055 | 1.292–7.223 |
| Baseline hemoglobin level | 0.523 | 0.335–0.816 | ||
| Poor ART adherence | 27.848 | 8.928–86.863 | ||
|
| ||||
| (2) | Tsehaineh B. et al., unpublished | Old age | 1.03 | 1.01–1.051 |
| CD4 count at baseline | 0.994 | 0.992–0.996 | ||
| Weight at baseline | 0.902 | 0.816–0.996 | ||
| Bedridden functional status | 6.904 | 4.005–11.902 | ||
| Ambulatory functional status | 2.877 | 1.899–4.360 | ||
| Coinfection with TB | 1.906 | 1.305–2.784 | ||
| Substance use | 1.42 | 1.016–1.985 | ||
|
| ||||
| (3) | Setegn et al., 2015 | Male | 2.67 | 1.74–4.10 |
| Bedridden clients | 4.4 | 1.55–12.36 | ||
| TB coinfected at ART initiation | 4.51 | 2.86–7.11 | ||
| Primary education | 0.28 | 0.11–0.70 | ||
| Secondary education | 0.34 | 0.154–0.728 | ||
| WHO stage 1 | 0.16 | 0.08–0.33 | ||
| WHO stage 2 | 0.34 | 0.16–0.73 | ||
| WHO stage 3 | 0.24 | 0.13–0.43 | ||
|
| ||||
| (4) | Biadgilign S. et al., 2012 | WHO stage IV | 3.19 | 1.51–6.76 |
| Bedridden | 4.09 | 2.12–7.90 | ||
| >10% weight loss from baseline | 4.93 | 1.20–20.41 | ||
| CD4 | 0.40 | 0.17–0.93 | ||
| Education | 2.79 | 1.26–6.16 | ||
|
| ||||
| (5) | Kassa A. et al., 2012 | CD4 < 50 cells/μl | 1.80 | 1.17–2.83 |
| WHO stage III | 1.46 | 1.03–2.08 | ||
| WHO stage IV | 2.72 | 1.91–3.88 | ||
| Those who developed TB after ART | 1.60 | 1.19–2.15 | ||
| Ambulatory functional status | 1.44 | 1.07–1.93 | ||
| Bedridden functional status | 2.95 | 2.10–4.13 | ||
|
| ||||
| (6) | Seyoum D. et al., 2017 | Age > 35 | 3.8 | 1.6–9.1 |
| Baseline weight | 0.93 | 0.90–0.97 | ||
| Baseline WHO stage IV | 6.2 | 2.2–14.2 | ||
| Low adherence to ART | 4.2 | 2.5–7.1 | ||
|
| ||||
| (7) | Damtew B. et al., 2015 | Single marital status | 2.31 | 1.18–4.50 |
| Bedridden functional status | 5.91 | 2.87–12.16 | ||
| Advanced WHO stage | 7.36 | 3.17–17.12 | ||
| BMI < 18.5 kg/m2 | 2.20 | 1.18–4.09 | ||
| CD4 count < 50 cells/μL | 2.70 | 1.26–5.80 | ||
| Severe anemia | 4.57 | 2.30–9.10 | ||
| TB coinfection | 2.30 | 1.28–4.11 | ||
|
| ||||
| (8) | Alemu AW and Sebastian MS, 2010 | Hemoglobin < 10 g/dL | 2.56 | 1.11–5.88 |
| WHO stage IV | 5.13 | 2.33–11.33 | ||
| Not on cotrimoxazole prophylaxis | 7.14 | 2.7–20.00 | ||
|
| ||||
| (9) | Ayalew et al., 2014 | Age 30–40 | 0.49 | 0.28–0.85 |
| Rural residency | 1.74 | 1.11–2.74 | ||
| CD4 count | 0.998 | 0.996–0.999 | ||
| Weight | 0.968 | 0.943–0.993 | ||
| Not working functional status | 3.62 | 1.96–6.68 | ||
| Lymphocyte count | 0.969 | 0.945–0.994 | ||
| WHO stage IV | 2.38 | 1.21–4.63 | ||
| TB positive | 1.87 | 1.03–3.40 | ||
|
| ||||
| (10) | Ahunie MA and Ebrahim EA | Ambulatory functional status | 4.2 | 1.7–10.7 |
| Bedridden functional status | 6.5 | 2.0–20.7 | ||
| Poor antiretroviral drug adherence | 5.1 | 1.6–16.3 | ||
|
| ||||
| (11) | Abebe N et al., 2014 | Baseline hemoglobin < 10 g/mm3 | 1.86 | 1.39–2.64 |
| Ambulatory functional status | 2.72 | 1.90–3.90 | ||
| Bedridden functional status | 2.38 | 1.32–4.27 | ||
| WHO stages III and IV | 2.16 | 1.10–4.25 | ||
| Poor adherence | 2.16 | 1.03–4.56 | ||
| Fair adherence | 1.88 | 1.08–3.29 | ||
| Unexplained chronic diarrhea | 1.53 | 1.09–2.15 | ||
| Not on TB prophylaxis | 3.98 | 1.87–8.44 | ||
|
| ||||
| (12) | Tadesse K et al., 2014 | Hemoglobin level < 11 mg/dl | 1.9 | 1.01–3.52 |
| CD4 cell count < 50 cells/μl | 2.1 | 1.13–3.89 | ||
| Male gender | 1.9 | 1.01–3.52 | ||
| Weight < 40 kg | 2.3 | 1.24–4.55 | ||
| Primary and lower level of education | 2.6 | 1.29–5.55 | ||
|
| ||||
| (13) | Bedru A. and worku A, unpublished | Poor ART adherence | 3.92 | 3.13–4.90 |
| Advanced WHO staging | 2.47 | 1.58–3.81 | ||
| Being unemployed | 1.87 | 1.49–2.34 | ||
| Moderate anemia | 1.86 | 1.35–2.56 | ||
| Low CD4 count | 1.85 | 1.35–2.52 | ||
|
| ||||
| (14) | Mengesha S et al., 2014 | WHO clinical stage | 2.99 | 1.26–5.31 |
| Anemia | 5.54 | 2.58–11.86 | ||
| Having past TB coinfection | 4.13 | 1.79–9.51 | ||
|
| ||||
| (15) | Moshago T et al., 2012 | WHO clinical stage IV | 4.5 | 1.36–14.88 |
| WHO clinical stage III | 3.2 | 1.06–10.24 | ||
| History of TB coinfection | 1.25 | 1.03–1.53 | ||
| Bedridden functional status | 2.63 | 2.05–3.37 | ||
| Ambulatory functional status | 1.56 | 1.31–1.86 | ||
|
| ||||
| (16) | Sapa et al., 2016 | BMI < 18.5 kg/m2 | 3.12 | 1.39–7.76 |
| CD4 cell count < 50 cells/mm3 | 4.55 | 1.19–8.44 | ||
| Drug addiction | 2.03 | 1.11–4.56 | ||
| WHO stages III and IV | 11.25 | 8.67–17.96 | ||
| Severe anemia | 5.14 | 3.12–9.65 | ||
|
| ||||
| (17) | Kebebew K and Wencheko E, 2012 | CD4 cell count at baseline | 0.78 | 0.64–0.95 |
| Employment status | 2.31 | 1.25–4.28 | ||
| Ambulatory functional status | 2.01 | 1.02–3.98 | ||
| Bedridden functional status | 3.36 | 1.73–6.50 | ||
| WHO clinical stage III | 7.05 | 1.68–29.66 | ||
| WHO clinical stage IV | 12.64 | 3.00–53.20 | ||
| TB coinfection | 1.73 | 1.04–2.89 | ||
| Presence of opportunistic infections | 8.99 | 1.24–65.09 | ||